Finally, additional trials to follow on successful initial results are required in the case of appendiceal carcinomas with GNAS mutations and to further elucidate the mechanisms of sensitivity or resistance of these cancers to CDK4/6 inhibitors. This evidence concerns the gene GNAS and cancer.